Cardiovascular Evaluations of a Mixed Extract of <i>Salvia Miltiorrhiza Bunge</i> and <i>Paeonia Lactiflora</i> Pall. (USCP-GVH-014): A 12 Weeks Clinical Perspective

<i>Salvia miltiorrhiza Bunge</i> and <i>Paeonia lactiflora</i> Pall. are traditionally used to manage cardiovascular health. However, clinical evidence evaluating standardized extracts for specific cardiovascular benefits is still evolving. This study aimed to evaluate its efficacy and safety of a mixed extract of <i>S. miltiorrhiza Bunge</i> and <i>P. lactiflora</i> Pall. (USCP-GVH-014) for improving cardiovascular function in adults with early-stage vascular health decline. This 12-week, single-center, single-arm, prospective exploratory clinical trial enrolled 30 adults with at least two risk factors. Participants consumed USCP-GVH-014 (1200 mg/day), and outcomes included systolic blood pressure (SBP), carotid intima-media thickness (CIMT), lipid metabolism markers, and inflammatory markers, which were assessed at baseline, 6 weeks, and 12 weeks. USCP-GVH-014 significantly reduced SBP over time (<i>P</i> = .013), particularly at 12 weeks (<i>P</i> = .007). Total cholesterol significantly decreased at 6 weeks (<i>P</i> = .035), though the effect was not sustained at 12 weeks. Low-density lipoprotein cholesterol demonstrated a significant overall reduction (<i>P</i> = .031), but post-hoc comparisons did not confirm the significance between specific time points. CIMT significantly decreased after 12 weeks (<i>P</i> < .001). Additionally, improvements were observed in mean arterial pressure (<i>P</i> = .008), pulse pressure (<i>P</i> = .04), heart rate (<i>P</i> = .013), and right pulse wave velocity (<i>P</i> = .043). No serious adverse events related to the product were reported. USCP-GVH-014 may enhance vascular health by lowering SBP, reducing CIMT, and modulating lipid metabolism, highlighting its potential as a functional ingredient for cardiovascular health support.